Renca Syngeneic Model Service for Renal Cancer

The Renca syngeneic model service for renal cancer is an immune-competent BALB/c platform built on the 1969 spontaneous renal cortical adenocarcinoma line whose growth pattern ATCC notes accurately mimics human adult renal cell carcinoma — particularly its spontaneous metastasis to lung and liver — across subcutaneous, orthotopic, and metastatic study formats. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated Renca / luciferase-RFP-engineered expansion and banking, intrarenal orthotopic or subcutaneous implantation with serial micro-CT and in vivo bioluminescence monitoring, and full renal histopathology with cytokeratin-8/18 tumor identification and checkpoint immunophenotyping — all configured around each sponsor’s TKI, checkpoint, combination, or vascular-targeting hypothesis.

Overview of Renca Syngeneic Model for Renal Cancer

Renca is among the oldest continuously used renal tumor lines — derived from a spontaneous renal cortical adenocarcinoma that arose in a six-week-old male BALB/cCr mouse, first described by Murphy and Hrushevsky in the Journal of the National Cancer Institute in 1973, and deposited with the ATCC by Robert Wiltrout in 1969. The ATCC’s annotation for the line remains its best one-sentence summary: its pattern of growth accurately mimics human adult renal cell carcinoma, particularly with regard to spontaneous metastasis to lung and liver. The cells are epithelial, adhere as a cobblestone monolayer, double every 24 hours, and carry two documented molecular quirks — an absent transforming growth factor-β type II receptor (which inspired a dedicated literature on receptor-reconstitution tumor suppression) and a poorly immunogenic, highly tumorigenic character that nonetheless remains susceptible to NK-cell control, as the 1985 Salup study of natural killer activity in spontaneous metastasis established. Cytokeratin 8 and 18 staining serves as the standard immunohistochemical identifier of Renca tumor cells against host background.

Fig 1. Longitudinal in vivo bioluminescence imaging of orthotopic Renca-luc tumors from day 7 to day 28, with ex vivo lung/kidney imaging and H&E confirming metastatic spread—the standardized imaging pipeline of the Renca orthotopic model. (Liang, Zhihuang, et al., 2026)

In vivo, the model’s versatility mirrors its history: subcutaneous grafts (5 × 10⁶ cells) support rapid efficacy screening; intrarenal orthotopic implantation — 2 × 10⁵ luciferase-tagged cells beneath the renal capsule — produces a primary renal mass with lung metastasis by day 24, quantifiable by kidney wet weight, India-ink lung inflation, and serial in vivo bioluminescence; and luciferase-RFP engineering enables longitudinal tracking of both sites. The therapeutic record spans the entire modern RCC era: the IL-2-stimulated cytotoxic lymphocyte work of Wiltrout in 1986 belongs to the line’s heritage; the nucleoside analog BCH-4556 — later renamed troxacitabine and advanced to phase II trials — was characterized in Renca; the vascular-disruption agent BNC105 progressed from Renca orthotopic data into a pembrolizumab-combination clinical trial; and recent combination studies provide the model’s defining quantitative signature — median survival of 28 days untreated, 34 days with cabozantinib or anti-PD-1 alone, and 49 days with their combination, with RNA-sequencing of lung metastases revealing treatment-specific pathway rewiring (FGF upregulation after monotherapy, mTOR activation after combination) that now guides sequential-therapy design. One honest caveat from CRO benchmarking deserves equal prominence: Renca subcutaneous tumors do not respond to PD-1 monotherapy, making the model an ideal setting for combinations that must outperform TKI-plus-checkpoint standards rather than a stage for single-agent checkpoint claims. Engineered derivatives — Renca-IL2, CA-IX-expressing, lacZ-tagged, and sh-PD-L1 knockdown lines — extend the platform’s reach, and PD-L1 knockdown itself sensitizes the tumors to sunitinib with increased CD8 infiltration, illustrating the immunobiology the model was built to interrogate.

Cell Line Information: Renca

The table below consolidates the key biological, cultural, and modeling characteristics of the Renca line and its engineered derivatives.

Our Services

A model this historic rewards operational candor, and Alfa Cytology runs Renca with its benchmark data worn openly: STR-validated banks, validated subcutaneous and intrarenal formats with the 2 × 10⁵ orthotopic methodology, serial micro-CT and bioluminescence monitoring, and endpoint pathology with cytokeratin-8/18 identification and checkpoint immunophenotyping — all under one accountable preclinical operation, with the PD-1-monotherapy caveat stated in every study design.

Workflow of Renca Syngeneic Model Construction

Construction follows the published orthotopic and flank methodologies: Renca cells (parental or luciferase-RFP engineered) are expanded under authenticated conditions, implanted beneath the renal capsule or subcutaneously into BALB/c mice, tracked by imaging, treated after standardization, and analyzed with renal and metastatic endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: Renca or reporter derivatives are STR-profiled against the validated reference (per the PLoS ONE 2019 mouse-cell-line standard), confirmed mycoplasma-negative, and expanded into low-passage working banks under ATCC-formulated RPMI-1640 conditions.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at 2 × 10⁵ cells in 0.1 mL (intrarenal) or 5 × 10⁶ cells in 100 μL (subcutaneous) of HBSS or complete medium.
3. Anesthesia and implantation: BALB/c mice are anesthetized with isoflurane (or ketamine/xylazine per legacy protocols); cells are injected beneath the left renal capsule through a small flank approach with needle retention to minimize backflow, or implanted subcutaneously into the flank.
4. Establishment monitoring and randomization: Luciferase arms are imaged after D-luciferin administration from early timepoints; kidney and lung signals are quantified serially; animals are randomized at protocol-specified baselines balancing primary and metastatic burden.
5. Treatment administration: Experimental arms — TKIs (sunitinib, cabozantinib-class), checkpoint inhibitors alone and in combination, vascular-disruption agents, oncolytic viruses, and IL-2-era cellular products — proceed per study design with body-weight and toxicity monitoring.
6. Imaging and interim measurements: Serial in vivo bioluminescence tracks primary and lung kinetics; micro-CT sessions quantify renal mass and osteolytic change on the orthotopic format; interim blood draws profile circulating leukocytes where immune-context arms are designed.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-bearing kidney wet weight, lung-metastatic counts by India-ink inflation and histology, imaging kinetics, and survival with histopathology (H&E plus cytokeratin-8/18 tumor identification, Ki67, CD8, PD-L1, and CA-IX immunohistochemistry) and terminal immune-context profiling.

Fig 2. Renca Syngeneic Model construction workflow.

Case Study-Renca Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the Renca platform spanning TKI-plus-checkpoint combination evaluation, vascular-disruption agent screening, and orthotopic metastatic-burden tracking with luciferase-RFP engineering. In these studies, implanted Renca tumors were monitored through scheduled imaging and caliper measurements, treated per randomized regimens, and characterized at endpoint by histopathology with cytokeratin-8/18 identification and checkpoint immunophenotyping. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs historic-line stewardship with combination-therapy benchmarking discipline, so every Renca study is executed with validated orthotopic technique, published survival benchmarks as design references, and reporting that states the model’s checkpoint caveats plainly.

• Focused experience with Renca in subcutaneous and intrarenal orthotopic formats, including the 2 × 10⁵ Renca-GL methodology and luciferase-RFP tracking.
• A single coordinated team managing cell banking, renal surgery, in vivo imaging and micro-CT, and endpoint pathology under one quality framework.
• Design fluency with TKI-plus-checkpoint combinations against the published 28/34/34/49-day survival benchmark, with the PD-1-monotherapy caveat stated upfront.
• Endpoint panels pairing cytokeratin-8/18 tumor identification with CD8/PD-L1/CA-IX immunohistochemistry and India-ink lung-inflation metastatic enumeration.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your renal cancer program needs the field’s most venerable syngeneic RCC platform — with spontaneous lung and liver metastasis, published combination benchmarks, and orthotopic imaging capability — Alfa Cytology is ready to build the study around your hypothesis. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the Renca syngeneic model service.

For research use only. Not intended for any clinical use.